SNOA · Sonoma Pharmaceuticals, Inc.
Market Cap
$6.27M
Shares
4.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.29
Open$1.28
Day$1.27–1.31
52W close$1.01–4.73
Avg vol 30d174K
Short int201K · 4.2% float · 1.0d
Short vol10%
DataAug 2024–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on Aug 30, 2024; bars on opposite sides are not compared.
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−41%
below
Price vs 50-day avg
+4%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
8%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
−51%
trailing
YTD return
−65%
this year
Relative strength
−64%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.20% of float · ▲ +2279.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
Gross margin
38%
contracting
EPS growth
+32%
Y/Y
Free cash flow
$-4.1M
Balance sheet
$3.4M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−41%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
8%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.20% of float · ▲ +2279.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 8%
Range high $5
vs 200-day avg -41%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNOA
this stock
Sonoma Pharmaceuticals, Inc.
|
$6.27M | -64.6% | +36.7% | — | 4.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -0.1% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.35B | -0.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 30, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNOA | -3.7% | +15.2% | -50.6% | +17.3% | -64.6% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -4.2% | +13.9% | -63.8% | +14.6% | -77.0% |
Key facts
CIK
1367083
CUSIP
83558L303
13F (30d)
12 filings
12 filers
Visit website
Investor relations